CRGY

Crescent Energy Co. (CRGY) - Form 8-K Summary

Business Context and Reporting Period

Date of Report: August 24, 2025
Company: Crescent Energy Company (Parent)
Counterparty: Vital Energy, Inc. (Company)
Event: Entry into a Material Definitive Agreement (Merger Agreement).

Crescent Energy Company has entered into an Agreement and Plan of Merger to acquire Vital Energy, Inc. in an all-equity transaction. The deal involves a two-step merger structure where Vital will first merge into a Crescent subsidiary and then into a second Crescent subsidiary, with Crescent continuing as the sole member of the surviving entity.

Key Financial Metrics and Transaction Terms

Transaction Consideration: All-equity exchange.
Exchange Ratio: 1.9062 shares of Crescent Class A Common Stock for each share of Vital Energy common stock.
Post-Closing Ownership:

• Crescent Stockholders: Approximately 77%
• Vital Stockholders: Approximately 23%

Termination Fees:

• Company Termination Fee (payable by Vital): $22,500,000
• Parent Termination Fee (payable by Crescent): $76,900,000

Management Fee Cap: Incremental management fees related to the transaction will not exceed $9 million.
Financial Data: The filing text does not provide specific revenue, profit, cash flow, or debt metrics for either company; it focuses solely on the transaction structure.

Material Changes and Governance

Board Composition: Following the closing, the Crescent Board of Directors will increase to 12 members, including two directors designated by Vital Energy.
Support Agreements: Certain existing Crescent stockholders (collectively holding approximately 28% of the outstanding voting power) have entered into Voting and Support Agreements to vote in favor of the transaction and against competing proposals.
Equity Treatment:

• Stock options will be converted to Crescent options based on the exchange ratio.
• Time-based restricted stock awards will vest in full and convert to merger consideration.
• Performance-based cash-settled awards will vest at target levels and be paid in cash.

Conditions, Risks, and Outlook

Conditions to Closing:

• Approval by stockholders of both Crescent and Vital.
• Expiration of the HSR Act waiting period.
• Effectiveness of Crescent's Form S-4 registration statement.
• Listing of Crescent shares on the NYSE.
• Absence of laws or orders prohibiting the merger.

Termination Rights: Either party may terminate if the closing does not occur by March 31, 2026, or if stockholder approval is not obtained. Termination fees apply if the deal is terminated to pursue a superior proposal or due to a change in recommendation.
Risks: The filing highlights standard M&A risks, including the failure to obtain regulatory or stockholder approval, integration challenges, disruption of management focus, and the possibility that the combined company may not achieve anticipated synergies.

Investor Verification Checklist

• Stockholder Approval: Verify the outcome of the upcoming votes by both Crescent and Vital stockholders.
• Regulatory Clearance: Monitor the status of the Hart-Scott-Rodino (HSR) waiting period and any other antitrust reviews.
• Form S-4: Review the joint proxy statement/prospectus (Form S-4) once filed for detailed financial pro formas and risk factors.
• Competing Proposals: Watch for any announcements of superior proposals that could trigger termination fees or a change in recommendation.
• Closing Deadline: Note the March 31, 2026, deadline for the transaction to close.